SLV 321
Alternative Names: SLV-321Latest Information Update: 15 Feb 2006
At a glance
- Originator Solvay
- Class Irritable bowel syndrome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 15 Feb 2006 No development reported - Preclinical for Irritable bowel syndrome in USA (unspecified route)
- 25 Aug 2003 Preclinical trials in Irritable bowel syndrome in USA (unspecified route)